Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant

Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant

Angela Chiereghin,1,2 Tamara Belotti,3 Eva Caterina Borgatti,4 Nicola Fraccascia,5 Giulia Piccirilli,6 Maura Fois,3 Michele Borghi,4 Gabriele Turello,4 Liliana Gabrielli,6 Riccardo Masetti,3 Arcangelo Prete,3 Stefano Fanti,5 Tiziana Lazzarotto4 1Section of Microbiology, Department of Specialized, Ex...

Full description

Bibliographic Details
Main Authors: Chiereghin A, Belotti T, Borgatti EC, Fraccascia N, Piccirilli G, Fois M, Borghi M, Turello G, Gabrielli L, Masetti R, Prete A, Fanti S, Lazzarotto T
Format: Article
Language:English
Published: Dove Medical Press 2021-03-01
Series:Infection and Drug Resistance
Subjects:
pediatric allogeneic peripheral blood stem cell transplant
gcv-resistant cmv
intolerance to fos
off-label letermovir use.
Online Access:https://www.dovepress.com/off-label-use-of-letermovir-as-preemptive-anti-cytomegalovirus-therapy-peer-reviewed-article-IDR

Internet

https://www.dovepress.com/off-label-use-of-letermovir-as-preemptive-anti-cytomegalovirus-therapy-peer-reviewed-article-IDR

Similar Items